Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nowotwór jajnika, otrzewnej lub jajcowodu (Grupy A i B) lub zaawansowany rak macicy (Grupa C)
- •Oczekiwana długość życia co najmniej 3 miesiące
- •Dobry stan ogólny (skala ECOG 0-1)
- •Możliwość połykania i przyjmowania leków doustnych
- •Od 1 do 3 (lub 1-2 dla raka macicy) poprzednich linii chemioterapii
- •Prawidłowe funkcje narządów wewnętrznych
- •Ujemny test ciąży dla kobiet mogących zajść w ciążę
✗ Disqualifies
- •Wcześniejszy udział w badaniu z relacoreliantem
- •Niepowstrzymane skutki uboczne z poprzedniego leczenia
- •Operacja w ciągu 4 tygodni przed włączeniem do badania
- •Potrzeba częstego stosowania kortykosteroidów
- •Wysokie ciśnienie krwi (≥150/100 mm Hg)
- •Neuropatia obwodowa (ponad stopień 1)
- •Obstrukcja jelit w ciągu 12 tygodni przed badaniem
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 16, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (49)
004
Birmingham, United States
150
Palo Alto, United States
014
San Francisco, United States
544
Fort Myers, United States
335
Miami Beach, United States
543
West Palm Beach, United States
518
Minneapolis, United States
334
Kansas City, United States
521
St Louis, United States
292
Albuquerque, United States
304
Centerville, United States
517
Eugene, United States
127
Pittsburgh, United States
522
Fairfax, United States
300
Norfolk, United States
121
Milwaukee, United States
328
Aalst, Belgium
326
Charleroi, Belgium
325
Hasselt, Belgium
108
Leuven, Belgium
306
Lille, France
307
Nancy, France
310
Nice, France
324
Pierre-Bénite, France
323
Plérin, France
308
Toulouse, France
519
Aachen, Germany
255
Berlin, Germany
520
Kempten, Germany
321
Catania, Italy
122
Milan, Italy
516
Milan, Italy
295
Pavia, Italy
124
Rome, Italy
293
Torino, Italy
319
Treviso, Italy
341
Gdynia, Poland
329
Siedlce, Poland
396
Seoul, South Korea
397
Gyeonggi-do, South Korea
399
Seoul, South Korea
523
Seoul, South Korea
398
Seoul, South Korea
403
Seoul, South Korea
349
Badalona, Spain
115
Barcelona, Spain
114
Madrid, Spain
558
Valencia, Spain
330
Valencia, Spain
Trial contact
Corcept Therapeutics
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.